Neurogene Inc. Company Profile
NASDAQ: NGNEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 1:05 PM ET
Neurogene at a glance
Neurogene Inc. (NASDAQ: NGNE) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in New York, NY, Canada. Neurogene is led by Dr. Rachel L. McMinn Ph.D. and employs about 131 people. The company's shares have traded publicly since 2014.
At a market capitalization of $530.3 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001404644, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Neurogene do?
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Business description based on the company's public filings.
Company information
- Legal name
- Neurogene Inc.
- Ticker
- NASDAQ: NGNE
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Rachel L. McMinn Ph.D.
- Employees
- 131
- Headquarters
- 535 W 24th Street, New York, NY, Canada
- Phone
- 855 508 3568
- Website
- neurogene.com
- IPO year
- 2014
- Market cap
- $530.30M
- SEC CIK
- 0001404644
Companies similar to Neurogene
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OCSOculis Holding AG | 8.60 | -0.69% | $529.66M | vs NGNE |
| PBYIPuma Biotechnology Inc | 10.26 | +2.86% | $529.36M | vs NGNE |
| DRUGBright Minds Biosciences Inc. | 54.72 | +5.23% | $539.76M | vs NGNE |
| BLSMBlossomHill Therapeutics Inc. | 17.11 | +1.33% | $543.68M | vs NGNE |
| CTMXCytomX Therapeutics Inc. | 2.50 | +1.17% | $544.49M | vs NGNE |
| EVOEvotec SE ADR | 1.54 | -2.23% | $545.52M | vs NGNE |
| EOLSEvolus Inc. | 7.74 | -0.77% | $511.23M | vs NGNE |
| MNPRMonopar Therapeutics Inc. | 82.05 | -2.30% | $550.70M | vs NGNE |